$5 Billion Bet: Isomorphic Labs Shatters AI Drug Discovery Funding Records Amid Industry Pivot to Clinical Validation

In a landmark move that underscores Silicon Valley and global sovereign wealth funds’ enduring conviction in artificial intelligence, Alphabet-backed AI drug discovery firm Isomorphic Labs announced on November 17 that it has closed a $5 billion Series C funding round.

Co-led by Greenoaks and Sequoia Capital, the round saw new participation from Andreessen Horowitz (a16z) alongside a substantial follow-on investment from parent company Alphabet. Existing backers, including Temasek, MGX, and the UK Sovereign AI Fund, also joined the financing. The raise sets a new all-time record for a single funding round in the AI-driven pharmaceutical sector, bringing Isomorphic Labs’ total publicly disclosed capital to $7.7 billion since its debut external raise in March 2025.

Despite commanding unprecedented capital, Isomorphic Labs faces a stark reality: the company has yet to advance a single drug candidate into human clinical trials.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply